)
)
Vanda Pharmaceuticals Investor Relations Material
Latest events
Q3 2024
Vanda Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Vanda Pharmaceuticals Inc
Access all reports
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ (tasimelteon) for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone) for the treatment of bipolar disorder. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder and smith-magenis syndrome; Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness; Fanapt oral tablets for the treatment of schizophrenia; Novel fixed dose combination products: anoro progesterone vaginal system/norethindrone acetate tablets in women
Latest articles
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
)
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
)
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
VNDA
Country
🇺🇸 United States